Search Within

Population Sciences Research Program

  1. "Clifford Hudis"
  2. "Diana Lake"
Formats
  1. Meeting Abstract (22)
  2. Journal Article (14)
Groups
  1. Breast Medicine Service (36)
  2. Department of Medicine (36)
  3. Solid Tumor Oncology Division (36)
  4. Survivorship Research (36)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (35)
  6. Epidemiology and Biostatistics (34)

More Groups

People
  1. Clifford Hudis (36)
  2. Diana Lake (36)
  3. Larry Norton (29)
  4. Gabriella D'Andrea-Carlino (28)
  5. Chau Dang (27)
  6. Monica Fornier (27)

More People

Years
  1. 2019 (1)
  2. 2017 (3)
  3. 2016 (2)
  4. 2015 (3)
  5. 2014 (4)
  6. 2013 (3)

More Years

Publications
  1. Journal of Clinical Oncology (11)
  2. Breast Cancer Research and Treatment (7)
  3. Cancer Research (7)
  4. Clinical Breast Cancer (4)
  5. Clinical Cancer Research (4)
  6. Annals of Oncology (2)

More Publications

Publishers
  1. American Association for Cancer Research (11)
  2. American Society of Clinical Oncology (11)
  3. Springer (7)
  4. Elsevier Inc. (4)
  5. Oxford University Press (2)
  6. American Medical Association (1)

Results (36)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of gemcitabine with trastuzumab and pertuzumab after prior pertuzumab-based therapy among patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A phase 2 clinical trial
    Journal Article

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Fornier, M. N.; Goldfarb, S.; Jhaveri, K.; more...
    JAMA Network Open (2019)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P. A.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M.; Goldfarb, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A pilot study of dose-dense paclitaxel with trastuzumab and lapatinib for node-negative HER2-overexpressed breast cancer
    Journal Article

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S. M.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G. M.; Drullinsky, P. R.; Gajria, D.; Goldfarb, S. B.; Comen, E. A.; more...
    Clinical Breast Cancer (2016)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save